Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans

被引:208
作者
Dickmann, LJ
Rettie, AE
Kneller, MB
Kim, RB
Wood, AJJ
Stein, CM
Wilkinson, GR
Schwarz, UI
机构
[1] Vanderbilt Univ, Sch Med, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA
[2] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA
[3] Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN 37232 USA
关键词
D O I
10.1124/mol.60.2.382
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2C9 is a polymorphic gene for which there are four known allelic variants; CYP2C9*1, CYP2C9*2, CYP2C9*3, and CYP2C9*4. In the present study, DNA from 140 European Americans and 120 African Americans was examined by single-strand conformational polymorphism and restriction fragment length polymorphism analyses, resulting in the identification of a new CYP2C9 variant, CYP2C9*5. This variant is derived from a C1080G transversion in exon 7 of CYP2C9 that leads to an Asp360Glu substitution in the encoded protein. The CYP2C9*5 variant was found to be expressed only in African Americans, such that approximately 3% of this population carries the CYP2C9*5 allele. The variant expressed in, and purified from, insect cells infected with a recombinant baculovirus. Comparative kinetic studies using the purified wild-type protein CYP2C9*1; the IIe359Leu variant, CYP2C9*3; and the Asp 360Glu variant CYP2C9*5 were carried out using (S)-warfarin, diclofenac, and lauric acid as substrates. The major effect of the Asp360Glu mutation was to increase the K-m value relative to that of CYP2C9*1 for all three substrates: 12-fold higher for (S)-warfarin 7-hydroxlation, 5-fold higher for the 4'-hydroxylation of ldiclofnac and 3-fold higher for the omega -1 hydroxlation of lauric acid, V-max values differed less that K-m values between the CYp2C9*1 and CYP2C9*5 proteins. In vitro intrinsic clearances for CYP2C9*5 calculated as the ratio of V-max/K-m, ranged fro 8 to 18% of CYP2C9*1 values. The corresponding ratio for CYP2C9*3 was 4 to 13%. Accordingly, the in vitro data suggest that carriers of the CYP2C9*5 allele would eliminate CYP2C9 substrates at slower rates relative to person expressing the wild-type protein.
引用
收藏
页码:382 / 387
页数:6
相关论文
共 35 条
  • [21] Structural flexibility and functional versatility of cytochrome P450 and rapid evolution
    Negishi, M
    Iwasaki, M
    Juvonen, RO
    Sueyoshi, T
    Darden, TA
    Pedersen, LG
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1996, 350 (01) : 43 - 50
  • [22] Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication
    Ninomiya, H
    Mamiya, K
    Matsuo, S
    Ieiri, I
    Higuchi, S
    Tashiro, N
    [J]. THERAPEUTIC DRUG MONITORING, 2000, 22 (02) : 230 - 232
  • [23] A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin
    Rettie, AE
    Haining, RL
    Bajpai, M
    Levy, RH
    [J]. EPILEPSY RESEARCH, 1999, 35 (03) : 253 - 255
  • [24] IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9
    RETTIE, AE
    WIENKERS, LC
    GONZALEZ, FJ
    TRAGER, WF
    KORZEKWA, KR
    [J]. PHARMACOGENETICS, 1994, 4 (01): : 39 - 42
  • [25] Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C5
    Richardson, TH
    Griffin, KJ
    Jung, F
    Raucy, JL
    Johnson, EF
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 338 (02) : 157 - 164
  • [26] ARACHIDONIC-ACID METABOLISM BY HUMAN CYTOCHROME P450S-2C8, CYTOCHROME P450S-2C9, CYTOCHROME P450S-2E1, AND CYTOCHROME P450S-1A2 - REGIOSELECTIVE OXYGENATION AND EVIDENCE FOR A ROLE FOR CYP2C ENZYMES IN ARACHIDONIC-ACID EPOXYGENATION IN HUMAN LIVER-MICROSOMES
    RIFKIND, AB
    LEE, C
    CHANG, TKH
    WAXMAN, DJ
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 320 (02) : 380 - 389
  • [27] ETHNICITY AS A VARIABLE IN EPIDEMIOLOGIC RESEARCH
    SENIOR, PA
    BHOPAL, R
    [J]. BRITISH MEDICAL JOURNAL, 1994, 309 (6950) : 327 - 330
  • [28] Genetic association between sensitivity to warfarin and expression of CYP2C9*3
    Steward, DJ
    Haining, RL
    Henne, KR
    Davis, G
    Rushmore, TH
    Trager, WF
    Rettie, AE
    [J]. PHARMACOGENETICS, 1997, 7 (05): : 361 - 367
  • [29] Genetic analysis of the human cytochrome P450 CYP2C9 locus
    Stubbins, MJ
    Harries, LW
    Smith, G
    Tarbit, MH
    Wolf, CR
    [J]. PHARMACOGENETICS, 1996, 6 (05): : 429 - 439
  • [30] The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism
    SullivanKlose, TH
    Ghanayem, BI
    Bell, DA
    Zhang, ZY
    Kaminsky, LS
    Shenfield, GM
    Miners, JO
    Birkett, DJ
    Goldstein, JA
    [J]. PHARMACOGENETICS, 1996, 6 (04): : 341 - 349